7-phenyl-1H-indole | 1863-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-phenyl-1H-indole
• CAS: 1863-21-4
• 化学式: C₁₄H₁₁N
• 分子量: 193.248
• InChiKey: PIEDFMITVNDHRR-UHFFFAOYSA-N

物化性质

• 熔点：
  124-125 °C
• 沸点：
  392.5±11.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  7-phenyl-1H-indole 在 sodium cyanoborohydride 作用下， 以 溶剂黄146 为溶剂， 反应 3.0h， 以95%的产率得到7-phenylindoline
  参考文献：
  名称：

  Pyridazine N-Oxides as Precursors of Metallocarbenes: Rhodium-Catalyzed Transannulation with Pyrroles

  摘要：

  Pyridazine N-oxides are used for the first time as precursors of metallocarbenes. These nitrogen-rich heterocycles led to the discovery of a novel acceptor and donor-acceptor enalcarbenoids. The synthetic utility of these metallocarbenes was demonstrated in the rhodium-catalyzed denitrogenative transannulation of pyridazine N-oxides with pyrroles to the valuable alkyl, 7-aryl, and 7-styryl indoles. The transannulation strategy was applied to the synthesis of a potent anticancer agent.

  DOI：

  10.1021/acs.orglett.5b03064
• 作为产物：
  描述：

  7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2-trimethylsilanyl-indole-1-carboxylic acid diethylamide 在 potassium phosphate 、 四(三苯基膦)钯 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 7-phenyl-1H-indole
  参考文献：
  名称：

  定向原位金属化方法用于C-7取代的吲哚。Suzuki-Miyaura交叉偶联和吡咯并菲蒽酮生物碱的合成。

  摘要：

  [反应：见正文]尽管吲哚N-膦酰基衍生物4经过n-BuLi脱质子/亲电淬灭以提供C-7取代的产物，但其脱保护需要苛刻的条件。另一方面，N-酰胺12经连续或一锅C-2金属化，甲硅烷基化，C-7金属化和亲电处理后，以良好的总收率提供吲哚7。与Suzuki-Miyaura规程结合使用，可获得C-7芳基（杂芳基）取代的吲哚14和16，包括吡咯并菲蒽酮生物碱家族的成员Hippadine和pratosine。

  DOI：

  10.1021/ol0344772

文献信息

• Expedient cobalt(<scp>ii</scp>)-catalyzed site-selective C7-arylation of indolines with arylboronic acids
  作者：Pinaki Bhusan De、Sourav Pradhan、Sonbidya Banerjee、Tharmalingam Punniyamurthy

  DOI：10.1039/c8cc00395e

  日期：——

  Cobalt(II)-catalyzed pyrimidyl directing group-assisted C7 arylation of indolines with arylboronic acids has been developed using Mn(OAc)2·4H2O as an oxidant. The use of cobalt(II)–PCy3 as a catalyst and broad substrate scope are the important practical features.

  使用Mn（OAc）2 ·4H 2 O作为氧化剂，已经开发了钴（II）催化的吲哚啉与芳基硼酸的嘧啶导向基团辅助的C7芳基化反应。重要的实用功能是使用钴（II）–PCy 3作为催化剂和广泛的底物范围。
• Iron(II)‐Catalyzed Aerobic Biomimetic Oxidation of N‐Heterocycles
  作者：Srimanta Manna、Wei‐Jun Kong、Jan‐E. Bäckvall

  DOI：10.1002/chem.202102483

  日期：2021.10

  Herein, an iron(II)-catalyzed biomimetic oxidation of N-heterocycles under aerobic conditions is described. The dehydrogenation process, involving several electron-transfer steps, is inspired by oxidations occurring in the respiratory chain. An environmentally friendly and inexpensive iron catalyst together with a hydroquinone/cobalt Schiff base hybrid catalyst as electron-transfer mediator were used

  本文描述了有氧条件下铁(II)催化的N-杂环的仿生氧化。脱氢过程涉及多个电子转移步骤，其灵感来自于呼吸链中发生的氧化。环境友好且廉价的铁催化剂与作为电子转移介体的氢醌/钴席夫碱杂化催化剂一起用于各种N-杂环的底物选择性脱氢反应。该方法显示出广泛的底物范围，并以良好至优异的产率提供重要的杂环化合物。
• Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
  申请人：Buck A. Elizabeth

  公开号：US20070280928A1

  公开（公告）日：2007-12-06

  The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).

  本发明提供了一种治疗患者体内NSCL、胰腺、结肠或乳腺癌肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是mTOR抑制剂，可以附加其他药物或治疗，如其他抗癌药物或放射治疗。本发明还提供了一种治疗患者体内肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是一种能够结合并直接抑制mTORC1和mTORC2激酶的mTOR抑制剂。本发明还提供了一种制药组合物，包括一种能够结合并直接抑制mTORC1和mTORC2激酶的EGFR激酶抑制剂和mTOR抑制剂，以及一种药用载体。本发明中可用于实施该方法的EGFR激酶抑制剂的首选示例是化合物厄洛替尼盐酸盐（也称为TARCEVA®）。
• Palladium-Catalyzed Suzuki−Miyaura Cross-Coupling Reactions of Potassium Aryl- and Heteroaryltrifluoroborates
  作者：Gary A. Molander、Betina Biolatto

  DOI：10.1021/jo0342368

  日期：2003.5.1

  heteroaryltrifluoroborates in Suzuki-Miyaura cross-coupling reactions is presented. The coupling of aryl- and electron-rich heteroaryltrifluoroborates with aryl and activated heteroaryl bromides proceeds readily under ligandless conditions. When deactivated aryl- and heteroaryltrifluoroborates are coupled with aryl and heteroaryl bromides and chlorides, a low loading (0.5-2%) of PdCl(2)(dppf).CH(2)Cl(2) efficiently

  提出了对Suzuki-Miyaura交叉偶联反应中芳基三氟硼酸钾和杂芳基三氟硼酸钾的反应性的扩展研究。富芳基和电子富集的杂芳基三氟硼酸酯与芳基和活化的杂芳基溴化物的偶联在无配体条件下容易进行。当钝化的芳基和杂芳基三氟硼酸酯与芳基和杂芳基溴化物和氯化物偶联时，PdCl（2）（dppf）.CH（2）Cl（2）的低负载量（0.5-2％）有效催化反应。在任何一种条件下，反应通常可以在露天气氛中进行。
• Synthesis of 2,5-Dihydroxy-3-(indol-3-yl)benzoquinones by Acid-Catalyzed Condensation of Indoles with 2,5-Dichlorobenzoquinone
  作者：Michael C. Pirrung、Liu Deng、Zhitao Li、Kaapjoo Park

  DOI：10.1021/jo0204597

  日期：2002.11.1

  conjugate addition of indoles to 2,5-dichlorobenzoquinone have been developed. A wide variety of indoles substituted with halogen, alkyl, alkoxy, and aryl groups participate in anaerobic condensation reactions promoted by HCl, H2SO4, or CH3CO2H. The hydroquinone product is partially oxidized by excess dichlorobenzoquinone and fully converted to the 2,5-dichloro-3-(indol-3-yl)benzoquinone targets by

  已经开发了三种将吲哚偶联到2，5-二氯苯醌上的方法。各种被卤素，烷基，烷氧基和芳基取代的吲哚参与HCl，H2SO4或CH3CO2H促进的厌氧缩合反应。对苯二酚产物被过量的二氯苯醌部分氧化，并通过DDQ或Ag2CO3氧化完全转化为2,5-二氯-3-（吲哚-3-基）苯醌目标。可以通过碱水解从二氯化物获得2，5-二羟基-3-（吲哚-3-基）苯醌。在这些反应中产生的联芳基键的旋转特性已经通过理论和光谱方法进行了检验。